Allos Therapeutics Inc - Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)
May 23 2008 - 7:15AM
Edgar (US Regulatory)
Issuer Free
Writing Prospectus
Filed pursuant to Rule 433
Registration
Statement No. 333-143198
(Supplementing
Preliminary Prospectus Supplement
dated May 19,
2008)
10,800,000 Shares
Allos Therapeutics, Inc.
Common Stock
This free writing prospectus relates
only to the securities described below and should be read together with the
preliminary prospectus supplement dated May 19, 2008 (including the base
prospectus dated June 5, 2007 and the documents incorporated by reference
therein) relating to these securities.
Terms and
Conditions of the Common Stock Offering
Number of Shares of
Common Stock
|
|
10,800,000
|
|
|
|
Overallotment Option
|
|
1,620,000
|
|
|
|
Public Offering Price
per Share
|
|
$5.64
|
|
|
|
Purchases by Certain
Stockholders
|
|
Warburg Pincus Private
Equity VIII, L.P. has indicated an interest in purchasing up to 3,500,000
shares of common stock at the public offering price. Baker Brothers Life
Sciences, L.P. and certain other affiliated funds, have indicated an interest
in purchasing up to 1,500,000 shares of common stock at the public offering
price. Because indications of interest are not binding agreements or
commitments to purchase, these entities may purchase fewer or no shares in
this offering.
|
|
|
|
Underwriting Discounts
and Commissions per
Share
|
|
$0.3384
|
|
|
|
Proceeds
|
|
Approximately $56.6
million, or approximately $65.2 million if the underwriters overallotment
option is exercised in full, after deducting the underwriting discounts and
commissions and estimated offering expenses.
|
|
|
|
Trade Date
|
|
May 22, 2008
|
|
|
|
Settlement Date
|
|
May 29, 2008
|
|
|
|
Underwriters
|
|
Merrill Lynch, Pierce,
Fenner & Smith Incorporated, Banc of America Securities LLC and
Citigroup Global Markets Inc.
|
The
issuer has filed a registration statement (including a prospectus and
preliminary prospectus supplement thereto) with the Securities and Exchange
Commission, or SEC, for the offering to which this communication relates.
Before you invest, you should read the prospectus and preliminary prospectus
supplement in that registration statement (including the documents incorporated
by reference therein) and other documents the issuer has filed with the SEC for
more complete information about the issuer and this offering. You may get these
documents for free by visiting EDGAR on the SECs web site at www.sec.gov.
Alternatively, the issuer, any underwriter or any dealer participating in the
offering will arrange to send you the prospectus and preliminary prospectus
supplement if you request it by calling Merrill Lynch & Co. toll free
at 1-866-500-5408.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024